Inclusion Criteria:  Participants must be ≥ 18 years of age Histologically proven diagnosis of advanced solid tumors Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Participants must have HER2 expression in tumor tissue and/or with HER2 aberration detected in tumor or blood by means of validated assay (s) Body weight within [45 - 150 kg] (inclusive) Male and female participants including woman of childbearing potential must agree to follow contraceptive guidance Capable of giving signed informed consent  Exclusion Criteria:  Any clinically significant cardiac disease History of or current interstitial lung disease or pneumonitis Uncontrolled or unresolved acute renal failure Prior solid organ or hematologic transplant. Known positivity with human immunodeficiency virus (HIV), known active hepatitis A, B, and C, or uncontrolled chronic or ongoing infectious requiring parenteral treatment. Receipt of a live-virus vaccination within 28 days of planned treatment start Participation in a concurrent clinical study in the treatment period. Inadequate hematologic, hepatic and renal function Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.  The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.